We are studying a new treatment combining capecitabine and temozolomide for patients with specific types of locally advanced rectal cancer. The goal is to see if this combination improves tumor response and surgical outcomes.
We are studying how the LAIV flu vaccine affects the immune response in young children. This research aims to see how well it protects against flu and influences overall health.
We are studying a new sequencing tool to help decide the best treatment for metastatic breast cancer patients. The goal is to see if it improves survival and response compared to standard chemotherapy.
We are evaluating a new treatment, IMC-M113V, for people with chronic HIV infection who are already on medication. The study will help us understand its safety and how it affects the immune system.
We are testing a new method using cultured cells from the mouth to help people with limbal stem cell deficiency. This study aims to see if this treatment can improve eye health and vision.
We are studying a combination of immunotherapy and radiation therapy for patients with intermediate stage liver cancer who cannot have surgery. The goal is to see if this treatment can help shrink tumors and improve survival.
We are researching the combination of capivasertib and fulvestrant for patients with HR+/HER2- advanced breast cancer who have not responded to standard treatments. The study aims to evaluate treatment effectiveness and safety in real-world clinical practice.
We are studying whether lithium carbonate can improve behavior and communication in patients with TBR1-related neurocognitive disorder. This trial will also assess the treatment's safety and overall impact on quality of life.
We are exploring whether semaglutide can help people with obesity and resistant hypertension better control their blood pressure compared to a placebo. This study aims to assess if this approach is feasible.
We are studying how ozanimod may help limit brain changes in people with relapsing-remitting multiple sclerosis. The trial looks at its effects on disease activity, cognition, fatigue, and quality of life.
We are testing a new treatment, 2LPAPI®, for people with high-risk HPV infections to see if it helps clear the virus better than a placebo. The study also looks at safety and how the treatment affects cervical cell health.
We are exploring a new treatment strategy for elderly patients with heart failure and chronic kidney disease to see if it helps manage potassium levels better. This study compares a potassium binder with standard medications to improve patient outcomes.
We are studying a new gene-editing treatment for children with severe sickle cell disease. The trial aims to evaluate its safety and effectiveness in improving their health.
We are investigating how intranasal and intramuscular flu vaccines affect antibody levels in the nose. This research may help improve future vaccination methods.
We are studying whether a combination of nivolumab and ipilimumab works better than pazopanib alone for patients with advanced rare sarcomas. This trial will help us understand treatment effectiveness and patient quality of life.
We are comparing two eye implants to see which one better improves vision and is more cost-effective for patients with resistant diabetic macular edema. This study also looks at how these treatments affect quality of life.
We are evaluating whether lenvatinib can help patients with advanced GIST who did not respond to imatinib and sunitinib. This study compares its effects to a placebo to assess its potential benefits.
We are studying the effects of axitinib alone versus axitinib combined with pembrolizumab in patients with advanced papillary renal cell carcinoma. This research aims to find out which treatment may work better as a first-line option.
We are testing the medication Mosliciguat for individuals with pulmonary hypertension related to interstitial lung disease. The study aims to see if it helps improve heart function and walking ability.
We are studying whether a new medication, abelacimab, can effectively prevent blood clots in patients with gastrointestinal or genitourinary cancer. This trial compares it to the standard treatment, dalteparin.